Medy-Tox

(주)메디톡스 · KOSDAQ · 086900 · Industry: Manufacture of medicinal chemicals

Key metrics

Earnings

Revenue, Q3 2026₩59.3bn As of Sep 30, 2026 Source 1 ↗
Revenue QoQ-13.7% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Revenue YoY-2.8% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income, Q3 2026₩15.5bn As of Sep 30, 2026 Source 1 ↗
Operating income QoQ+226.0% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Operating income YoY+74.5% As of Sep 30, 2026 Source 1 ↗, Source 2 ↗

Share buybacks

Buyback decided, last 3 months₩0 As of Nov 19, 2026
Buyback decided, last 3 months, % of sharesNot available
Shares acquired, last 3 months₩0 As of Nov 19, 2026
Shares acquired, last 3 months, % of sharesNot available
Treasury shares cancelled, last 3 months₩76.7bn As of Sep 30, 2026 Source 1 ↗
Treasury shares cancelled (number), last 3 monthsNot available
Treasury shares cancelled, last 3 months, % of sharesNot available
Buyback decided, last 12 months₩13.0bn As of Jun 9, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗
Buyback decided, last 12 months, % of sharesNot available
Shares acquired, last 12 months₩13.0bn As of Jun 17, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗
Shares acquired, last 12 months, % of sharesNot available
Treasury shares cancelled, last 12 months₩153.4bn As of Sep 30, 2026 Source 1 ↗, Source 2 ↗
Treasury shares cancelled (number), last 12 monthsNot available
Treasury shares cancelled, last 12 months, % of sharesNot available

Potential dilution

CB/BW/EB issued, last 12 months₩0 As of Nov 19, 2026
Rights offering new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, last 12 months0 shares As of Nov 19, 2026
Potential new shares, % of sharesNot available
Conversion price adjustments, last 12 months0 As of Nov 19, 2026

Supply contracts

Supply contracts, last 12 months₩0 As of Nov 19, 2026
Supply contracts vs prior-year revenue0.0% As of Nov 19, 2026
Contracts without a KRW amount0 contracts without a KRW amount excluded As of Nov 19, 2026

Disclosure activity

DART filings, last 3 months6 As of Nov 19, 2026
DART filings, previous 3 months11 As of Nov 19, 2026

Insider transactions

Open-market buys, last 12 months (shares)7,489 shares As of Aug 3, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗
Open-market buys, last 12 months (amount)₩550m As of Aug 3, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗
Open-market sells, last 12 months (shares)0 shares As of Nov 19, 2026
Open-market sells, last 12 months (amount)₩0 As of Nov 19, 2026
Net open-market buying, last 12 months (shares)7,489 shares As of Aug 3, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗
Insiders who bought, last 12 months2 As of Aug 3, 2026 Source 1 ↗, Source 2 ↗, Source 3 ↗, Source 4 ↗, Source 5 ↗

Insider transactions (last 12 months)

Open-market buys: 7,489 shares (₩550m). Open-market sells: 0 shares (₩0). Net open-market buying: +7,489 shares. Insiders who bought: 2.

Trade dateInsider (role)TypeSharesPriceAmount
Sep 14, 2026Gim Min Ju (Non-registered officer)Other (New appointment)+220 shares——
Aug 3, 2026Jeong Hyeon Ho (Registered director, Controlling shareholder)Open-market buy+3,465 shares₩70,758₩245m
Jul 30, 2026Jeong Hyeon Ho (Registered director, Controlling shareholder)Open-market buy+450 shares₩71,100₩32m
Jul 29, 2026Jeong Hyeon Ho (Registered director, Controlling shareholder)Open-market buy+1,000 shares₩73,690₩74m
Jul 7, 2026Jeong Hyeon Ho (Registered director, Controlling shareholder)Open-market buy+1,254 shares₩79,012₩99m
Jun 26, 2026Jeong Hyeon Ho (Registered director, Controlling shareholder)Open-market buy+65 shares₩77,000₩5m
Jun 25, 2026Jeong Hyeon Ho (Registered director, Controlling shareholder)Open-market buy+1,250 shares₩75,924₩95m
Mar 27, 2026Cheon Yeong Ik (Registered director)Other (New appointment)+7,342 shares——
Mar 18, 2026Jeong Jin Hyang (Non-registered officer)Open-market buy+5 shares₩117,300₩586,500Reported late
Mar 3, 2026Jeong Jin Hyang (Non-registered officer)Other (New appointment)+35 shares——Reported late

Annual financials

YearRevenueOperating income
2025₩247.3bn₩17.0bn
2024₩228.6bn₩20.3bn
2023₩221.1bn₩17.3bn

Filing timeline